Contract
Updated on 9/4/2026
Delivers synthetic cells for drug discovery
$50/hr
Emeryville, CA, USA
In Person
100% on-site in Emeryville, California.
See people who can refer or advise you
Slingshot Biosciences develops and sells synthetic cells for drug discovery, clinical trials, medical testing, and cell therapy manufacturing. These standardized cells are offered on-demand or made-to-order, providing researchers with consistent, controllable materials that replace traditional biological materials to improve data reliability. The company differentiates itself by delivering standardized, customizable, and readily available synthetic cells that reduce variability, with a North American customer focus and emphasis on sustainability. Its goal is to make healthcare more accessible and equitable globally by enabling reliable research and development across biopharma and healthcare.
Company Size
51-200
Company Stage
Series A
Total Funding
$34M
Headquarters
Emeryville, California
Founded
2012
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
401(k) Retirement Plan
Company Equity
Performance Bonus
Parental Leave
Life Insurance
Pet Insurance
Paid Vacation
Slingshot Bio has launched ViaComp Ultra Amine, a compensation control for amine-reactive viability dyes and antibody panels in multiparameter flow cytometry. The cell mimic control is designed to support spectral unmixing and compensation across complex workflows. The product captures amine-reactive viability dyes and fluorophore-conjugated antibodies from multiple host species — including mouse, rat, hamster, rabbit, and human — in a single reagent. Each vial contains pre-mixed positive and negative control particles that generate well-separated peaks with the fluorescence spectrum being tested. The ready-to-use liquid format eliminates preparation requirements associated with traditional cell-based controls. ViaComp Ultra Amine is available through Slingshot Bio's commercial catalogue and is manufactured under ISO 9001 quality management standards. Slingshot Bio is based in Emeryville, California, and develops cell mimic controls for flow cytometry using semiconductor manufacturing techniques.
Slingshot Biosciences has appointed Jim Snook as Senior Vice President, Global Sales. Snook brings over 20 years of executive sales leadership experience in life sciences, most recently serving as Vice President, Commercial at Bio-Techne's Protein Sciences unit, where he led sales transformation efforts. Previously, Snook led Miltenyi Biotec's Americas commercial team, growing it into a market leader in cell and gene therapy manufacturing solutions. At Slingshot, he will oversee the global sales organisation, including business development, inside sales, distribution and field application scientists. The appointment comes as the company experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotech firms, clinical diagnostics laboratories and academic institutions. Slingshot Biosciences develops synthetic controls for flow cytometry that provide improved reproducibility and stability compared to traditional biological controls.
Slingshot Biosciences appoints Jim Snook as Senior Vice President, Global Sales. Mar 05, 2026, 09:30 ET Industry veteran brings extensive life sciences commercial leadership experience from Biotechne, Miltenyi Biotec, and Adaptive Biotechnologies EMERYVILLE, Calif., March 5, 2026 /PRNewswire/ - Slingshot Biosciences, the pioneer of synthetic cell mimic technology for flow cytometry controls, today announced the appointment of Jim Snook as Senior Vice President, Global Sales. In this role, Snook will lead the company's rapidly growing global sales organization, including management of Business Development Vice Presidents, Inside Sales and Distribution Managers, and Field Application Scientists. Snook brings more than two decades of executive sales leadership experience in the life sciences industry to Slingshot Biosciences. Most recently, he served as Vice President, Commercial for the Protein Sciences business unit at Bio-Techne, where he led the transformation of the sales organization to capture share and enable growth. Prior to Bio-Techne, Snook led the Americas commercial team at Miltenyi Biotec, growing the organization into the market leader in cell and gene therapy manufacturing and analytical solutions. "Jim's appointment marks a pivotal moment for Slingshot Biosciences as we accelerate our global growth," said Glenn Bilawsky, Chief Executive Officer of Slingshot Biosciences. "His proven track record of building high-performing sales organizations and driving substantial revenue growth at leading life sciences companies makes him the ideal leader to take our commercial efforts to the next level. Jim's deep understanding of the flow cytometry and cell therapy markets, combined with his expertise in scaling sales operations, will be instrumental in expanding our reach and serving our customers worldwide." Snook's appointment comes as Slingshot Biosciences experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotechnology firms, clinical diagnostics laboratories, and academic research institutions. His leadership will be critical in capitalizing on the growing demand for reproducible, high-quality biomarker controls in cell-based assay development and cell therapy manufacturing. "I'm thrilled to join Slingshot Biosciences at such an exciting time in the company's growth," said Jim Snook. "The platform represents a genuine breakthrough in addressing many of the challenges in complex cell analysis from robust assay development through scalable deployment... Slingshot has developed an enabling solution for the flow cytometry community, and our consultative team looks forward to bringing this technology to researchers, labs and manufacturers around the globe." About Slingshot Biosciences Slingshot Biosciences is transforming cell-based assay quality and reliability by providing precise, reproducible synthetic controls that enable faster scientific breakthroughs and positive patient impact. The company's patented platform combines advanced polymer chemistry with semiconductor manufacturing precision to create synthetic cell mimics that deliver unmatched reproducibility, long-term stability, and significant cost savings compared to traditional biological controls. Slingshot Biosciences serves customers in pharmaceutical, biotechnology, clinical diagnostics, and academic research worldwide. For more information, visit www.slingshotbio.com. Media Contact: SOURCE Slingshot Biosciences
Slingshot Biosciences, a pioneer in synthetic cell mimic technology for flow cytometry controls, has announced its expansion into the United Kingdom and European Union markets. The Emeryville, California-based company aims to provide researchers with faster access to its precision-engineered biomarker controls for cell-based assay development. Slingshot's proprietary platform produces synthetic cell mimics that eliminate variability inherent in traditional biological controls, achieving lot-to-lot consistency with coefficients of variation as low as 0.1%. The technology is already used by hundreds of pharmaceutical companies, biotechnology firms, contract research organisations and academic medical centres globally. CEO Glenn Bilawsky cited the UK and EU's dynamic life sciences markets, noting the regions house leading research institutions and cell therapy companies that prioritise scientific rigour and reproducibility in developing therapies.
Slingshot Biosciences launches TruCytes(TM) Potency CD20 & CD34 Stem Cell Gating Controls, standardizing critical readouts while slashing variability, time, and cost.